CG Oncology, Inc. - Common stock (CGON)

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock.

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder cancer treatment at AUA 2025.

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

The companies are working on treatments for a form of bladder cancer.

As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.

Stocks are higher this afternoon, after this morning's highly-anticipated CPI report met expectations.

CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients, with median DOR exceeding 27 months and no severe side effects.

Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.

CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024.